|
MechanismSLC7A5 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 2 A Phase IIa Study to Evaluate the Efficacy and Safety of NBQ72S in Breast Cancer Patients With Leptomeningeal Metastases, With or Without Brain Parenchymal Metastases
A phase IIa, single-arm, open-label study was conducted to evaluate the efficacy and safety of NBQ72S, in patients with leptomeningeal metastases from breast cancer. All patients will receive the study drug every 28 days until withdrawal from treatment.
100 Clinical Results associated with Nantong Materia Medica Bada Pharmaceutical Technology Co., Ltd.
0 Patents (Medical) associated with Nantong Materia Medica Bada Pharmaceutical Technology Co., Ltd.
100 Deals associated with Nantong Materia Medica Bada Pharmaceutical Technology Co., Ltd.
100 Translational Medicine associated with Nantong Materia Medica Bada Pharmaceutical Technology Co., Ltd.